Market Overview

JP Morgan Comments on Potential Combination Of Valeant And Zoetis, Remains Overweight VRX and Neutral on ZTS

Share:
Related VRX
Citron Compares Express Scripts To Philidor: 'Culprit Behind Pharmaceutical Price Gouging'
Bill Ackman's Pershing Square Q3 Shareholder Letter Weighs In On Valeant, Chipotle
Will Trump Break With Republicans And Push Major Drug Price Reform? (Investor's Business Daily)
Related ZTS
Watch These 5 Huge Put Purchases In Friday Trade
Pershing Square No Longer Holds A Position In Zoetis
Bill Ackman Comments on Zoetis (GuruFocus)

The bank sees Zoetis as an 'attractive, durable, cash-pay business to Valeant's portfolio' and that a deal would be minimal accretive to EPS in the next 12 months. However, the deal would bring benefits in the longer run by aiding multiple expansion. Synergies remain elusive to those trying to identify them

Latest Ratings for VRX

DateFirmActionFromTo
Nov 2016MizuhoDowngradesNeutralUnderperform
Nov 2016Morgan StanleyMaintainsOverweight
Nov 2016Rodman & RenshawDowngradesBuyNeutral

View More Analyst Ratings for VRX
View the Latest Analyst Ratings

Posted-In: Analyst Color Reiteration Analyst Ratings

 

Related Articles (VRX + ZTS)

View Comments and Join the Discussion!